http://www.ncbi.nlm.nih.gov/pubmed/22819129
http://www.medical-hypotheses.com/article/S0306-9877(12)00312-X/abstract
Its seems very interesting and useful to know further more specific details or is it just me?
One example being the 5ht2 agonism, would be interesting if they had anything more specific on that(2a? it feels like it sometimes). The kappa opioid agonism is also very interesting
Anyway if its been discussed feel feel to close this.
MXE Pharmacology according to abstract:
noncompetitive NMDA receptor antagonist
dopamine reuptake inhibitor
an agonist at:
dopamine D2
serotonin 5HT2
muscarinic cholinergic
sigma-1
opioid mu and k receptors
http://www.medical-hypotheses.com/article/S0306-9877(12)00312-X/abstract
Anyway it seemed like this fit in ADD and maybe someone here can share the full paper with me or outline it?Methoxetamine: From drug of abuse to rapid-acting antidepressant
Received 3 May 2012; accepted 5 July 2012. published online 23 July 2012.
Abstract
Methoxetamine is a dissociative anaesthetic showing pharmacodynamic similarities with its analogue ketamine, a medication with demonstrated rapid-acting antidepressant effects. Like ketamine and other arylcyclohexylamine compounds, methoxetamine is thought to be both a noncompetitive NMDA receptor antagonist and a dopamine reuptake inhibitor. Furthermore, it acts as an agonist at dopamine D2, serotonin 5HT2, muscarinic cholinergic, sigma-1, opioid mu and k receptors. The hypothesis is that methoxetamine can produce rapid antidepressant effects in patients with resistant and non-resistant unipolar and bipolar depression.
PII: S0306-9877(12)00312-X
doi:10.1016/j.mehy.2012.07.002
© 2012 Elsevier Ltd. All rights reserved.
Its seems very interesting and useful to know further more specific details or is it just me?
One example being the 5ht2 agonism, would be interesting if they had anything more specific on that(2a? it feels like it sometimes). The kappa opioid agonism is also very interesting
Anyway if its been discussed feel feel to close this.
MXE Pharmacology according to abstract:
noncompetitive NMDA receptor antagonist
dopamine reuptake inhibitor
an agonist at:
dopamine D2
serotonin 5HT2
muscarinic cholinergic
sigma-1
opioid mu and k receptors
